Literature DB >> 25355869

Polyreactivity and autoreactivity among HIV-1 antibodies.

Mengfei Liu1, Guang Yang2, Kevin Wiehe3, Nathan I Nicely3, Nathan A Vandergrift4, Wes Rountree3, Mattia Bonsignori4, S Munir Alam3, Jingyun Gao1, Barton F Haynes5, Garnett Kelsoe6.   

Abstract

UNLABELLED: It is generally acknowledged that human broadly neutralizing antibodies (bNAbs) capable of neutralizing multiple HIV-1 clades are often polyreactive or autoreactive. Whereas polyreactivity or autoreactivity has been proposed to be crucial for neutralization breadth, no systematic, quantitative study of self-reactivity among nonneutralizing HIV-1 Abs (nNAbs) has been performed to determine whether poly- or autoreactivity in bNAbs is a consequence of chronic antigen (Ag) exposure and/or inflammation or a fundamental property of neutralization. Here, we use protein microarrays to assess binding to >9,400 human proteins and find that as a class, bNAbs are significantly more poly- and autoreactive than nNAbs. The poly- and autoreactive property is therefore not due to the infection milieu but rather is associated with neutralization. Our observations are consistent with a role of heteroligation for HIV-1 neutralization and/or structural mimicry of host Ags by conserved HIV-1 neutralization sites. Although bNAbs are more mutated than nNAbs as a group, V(D)J mutation per se does not correlate with poly- and autoreactivity. Infrequent poly- or autoreactivity among nNAbs implies that their dominance in humoral responses is due to the absence of negative control by immune regulation. Interestingly, four of nine bNAbs specific for the HIV-1 CD4 binding site (CD4bs) (VRC01, VRC02, CH106, and CH103) bind human ubiquitin ligase E3A (UBE3A), and UBE3A protein competitively inhibits gp120 binding to the VRC01 bNAb. Among these four bNAbs, avidity for UBE3A was correlated with neutralization breadth. Identification of UBE3A as a self-antigen recognized by CD4bs bNAbs offers a mechanism for the rarity of this bNAb class. IMPORTANCE: Eliciting bNAbs is key for HIV-1 vaccines; most Abs elicited by HIV-1 infection or immunization, however, are strain specific or nonneutralizing, and unsuited for protection. Here, we compare the specificities of bNAbs and nNAbs to demonstrate that bNAbs are significantly more poly- and autoreactive than nNAbs. The strong association of poly- and autoreactivity with bNAbs, but not nNAbs from infected patients, indicates that the infection milieu, chronic inflammation and Ag exposure, CD4 T-cell depletion, etc., alone does not cause poly- and autoreactivity. Instead, these properties are fundamentally linked to neutralization breadth, either by the requirement for heteroligation or the consequence of host mimicry by HIV-1. Indeed, we show that human UBE3A shares an epitope(s) with HIV-1 envelope recognized by four CD4bs bNAbs. The poly- and autoreactivity of bNAbs surely contribute to the rarity of membrane-proximal external region (MPER) and CD4bs bNAbs and identify a roadblock that must be overcome to induce protective vaccines.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25355869      PMCID: PMC4301171          DOI: 10.1128/JVI.02378-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

2.  Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection.

Authors:  H J Ditzel; K Itoh; D R Burton
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

3.  Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7.

Authors:  S E Schwarz; J L Rosa; M Scheffner
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

4.  Half-life of polyreactive antibodies.

Authors:  G Sigounas; N Harindranath; G Donadel; A L Notkins
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

5.  Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.

Authors:  K N Subramanian; L E Weisman; T Rhodes; R Ariagno; P J Sánchez; J Steichen; L B Givner; T L Jennings; F H Top; D Carlin; E Connor
Journal:  Pediatr Infect Dis J       Date:  1998-02       Impact factor: 2.129

6.  UBE3A/E6-AP mutations cause Angelman syndrome.

Authors:  T Kishino; M Lalande; J Wagstaff
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

7.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

8.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses.

Authors:  Laurent Verkoczy; Yao Chen; Jinsong Zhang; Hilary Bouton-Verville; Amanda Newman; Bradley Lockwood; Richard M Scearce; David C Montefiori; S Moses Dennison; Shi-Mao Xia; Kwan-Ki Hwang; Hua-Xin Liao; S Munir Alam; Barton F Haynes
Journal:  J Immunol       Date:  2013-08-05       Impact factor: 5.422

10.  Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains.

Authors:  C L Achim; M P Heyes; C A Wiley
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

View more
  101 in total

Review 1.  Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire.

Authors:  Joel Finney; Akiko Watanabe; Garnett Kelsoe; Masayuki Kuraoka
Journal:  Immunol Rev       Date:  2019-09-27       Impact factor: 12.988

Review 2.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

3.  Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency.

Authors:  George K Lewis
Journal:  J Clin Invest       Date:  2015-05-18       Impact factor: 14.808

Review 4.  Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire.

Authors:  Yariv Wine; Andrew P Horton; Gregory C Ippolito; George Georgiou
Journal:  Curr Opin Immunol       Date:  2015-07-10       Impact factor: 7.486

5.  DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Authors:  Sachin Gupta; Emily S Clark; James M Termini; Justin Boucher; Saravana Kanagavelu; Celia C LeBranche; Sakhi Abraham; David C Montefiori; Wasif N Khan; Geoffrey W Stone
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

6.  Cross-Reactive Antigen Expressed by B6 Splenocytes Drives Receptor Editing and Marginal Zone Differentiation of IgG2a-Reactive AM14 Vκ8 B Cells.

Authors:  Kerstin Nündel; Purvi Mande; Stephanie L Moses; Patricia Busto; Jaime L Cullen; Madelyn R Schmidt; Mark J Shlomchik; Robert T Woodland; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2019-09-18       Impact factor: 5.422

7.  Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

Authors:  Jinghe Huang; Byong H Kang; Elise Ishida; Tongqing Zhou; Trevor Griesman; Zizhang Sheng; Fan Wu; Nicole A Doria-Rose; Baoshan Zhang; Krisha McKee; Sijy O'Dell; Gwo-Yu Chuang; Aliaksandr Druz; Ivelin S Georgiev; Chaim A Schramm; Anqi Zheng; M Gordon Joyce; Mangaiarkarasi Asokan; Amy Ransier; Sam Darko; Stephen A Migueles; Robert T Bailer; Mark K Louder; S Munir Alam; Robert Parks; Garnett Kelsoe; Tarra Von Holle; Barton F Haynes; Daniel C Douek; Vanessa Hirsch; Michael S Seaman; Lawrence Shapiro; John R Mascola; Peter D Kwong; Mark Connors
Journal:  Immunity       Date:  2016-11-15       Impact factor: 31.745

8.  Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.

Authors:  LaTonya D Williams; Gilad Ofek; Sebastian Schätzle; Jonathan R McDaniel; Xiaozhi Lu; Nathan I Nicely; Liming Wu; Caleb S Lougheed; Todd Bradley; Mark K Louder; Krisha McKee; Robert T Bailer; Sijy O'Dell; Ivelin S Georgiev; Michael S Seaman; Robert J Parks; Dawn J Marshall; Kara Anasti; Guang Yang; Xiaoyan Nie; Nancy L Tumba; Kevin Wiehe; Kshitij Wagh; Bette Korber; Thomas B Kepler; S Munir Alam; Lynn Morris; Gift Kamanga; Myron S Cohen; Mattia Bonsignori; Shi-Mao Xia; David C Montefiori; Garnett Kelsoe; Feng Gao; John R Mascola; M Anthony Moody; Kevin O Saunders; Hua-Xin Liao; Georgia D Tomaras; George Georgiou; Barton F Haynes
Journal:  Sci Immunol       Date:  2017-01-27

Review 9.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

10.  Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.

Authors:  Daniel T MacLeod; Nancy M Choi; Bryan Briney; Fernando Garces; Lorena S Ver; Elise Landais; Ben Murrell; Terri Wrin; William Kilembe; Chi-Hui Liang; Alejandra Ramos; Chaoran B Bian; Lalinda Wickramasinghe; Leopold Kong; Kemal Eren; Chung-Yi Wu; Chi-Huey Wong; Sergei L Kosakovsky Pond; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.